GlassScriptPhysician profile
Garrett Larson
NPI 1376075184
$3,403.01
in general payments reported to CMS, 2019-2025
28 companies · $19.00 in 2025
The $19.00 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $548 · 2022: $781 · 2023: $1,143 · 2024: $912 · 2025: $19.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,073.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $864.34 | 2021-2024 | |
| Novo Nordisk INC | $509.07 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $494.24 | 2021-2024 | Mounjaro, Trulicity, Emgality |
| Astrazeneca Pharmaceuticals LP | $254.80 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $168.63 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $161.46 | 2021-2024 | Gardasil 9, Vaxneuvance, M-M-R II |
| Pfizer INC. | $145.89 | 2021-2024 | |
| Abbott Laboratories | $126.18 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $77.89 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Daiichi Sankyo INC. | $69.92 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $64.04 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.26 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $53.12 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $52.79 | 2021-2024 | Veozah |
| Currax Pharmaceuticals LLC | $43.71 | 2022-2023 | Contrave |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $29.01 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.49 | 2021-2024 | Trulance, Xifaxan |
| Dexcom, INC. | $27.45 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $27.42 | 2021 | |
| Hologic Sales and Service, LLC | $26.25 | 2021 | |
| Corium, LLC | $19.80 | 2024 | Azstarys |
| Philips North America LLC | $18.84 | 2024 | (Ck7) Extended Holter |
| Inspire Medical Systems, INC. | $18.61 | 2023 | Inspire |
| Nestle Healthcare Nutrition INC. | $17.26 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.37 | 2023 | Quviviq |
| Lucid Diagnostics INC. | $13.26 | 2022 | |
| Coopersurgical, INC. | $12.61 | 2022 | |
| Organon LLC | $5.30 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.